logo-loader
viewMotif Bio PLC

Motif Bio's lender postpone's loan amortisation date by one month

Hercules Capital made this change in support of Motif Bio managing its cash runway as it advances its pipeline expansion strategy.

Antibiotics
With a meeting planned next month with the FDA, this is an important time for Motif

Motif Bio PLC (LON:MTFB, NASDAQ:MTFB), the antibiotics developer, has amended its financing arrangement with Hercules Capital.

Hercules has agreed to amend the company's loan and security agreement by shifting back the next amortisation by one month to the first day of next month.

This change means that the August payment will be interest only.

READ Motif Bio to meet US regulator on September 19 to discuss trial design

"As we continue to evaluate options to build our pipeline, we are fortunate to have the support of our investors, who understand and appreciate the opportunities that may lay ahead,” said Graham Lumsden, the chief executive officer of Motif.

Quick facts: Motif Bio PLC

Price: 0.4948 GBX

AIM:MTFB
Market: AIM
Market Cap: £1.69 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Motif Bio completes rolling submission of NDA for new antibiotic Iclaprim

Graham Lumsden, chief executive of Motif Bio Plc (LON:MTFB), tells Proactive's Andrew Scott they've completed a rolling submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for their new antibiotic Iclaprim. Lumsden says upon acceptance of the filing of...

on 18/6/18

RNS

Settlement Agreement

1 day, 12 hours ago

Holding(s) in Company

2 weeks, 1 day ago

Holding(s) in Company

2 weeks, 4 days ago

Second Price Monitoring Extn

2 weeks, 5 days ago

Price Monitoring Extension

2 weeks, 5 days ago

2 min read